Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S. Castillo JJ, et al. Among authors: tsakmaklis n. Blood. 2024 Feb 15;143(7):582-591. doi: 10.1182/blood.2023022420. Blood. 2024. PMID: 37971194 Free PMC article.
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X, Chen J, Manning RJ, Chen JG, Brodsky P, Patterson CJ, Gustine J, Dubeau T, Castillo JJ, Anderson KC, Munshi NM, Treon SP. Hunter ZR, et al. Among authors: tsakmaklis n. Blood. 2016 Aug 11;128(6):827-38. doi: 10.1182/blood-2016-03-708263. Epub 2016 Jun 14. Blood. 2016. PMID: 27301862 Free PMC article.
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP. Xu L, et al. Among authors: tsakmaklis n. Blood. 2017 May 4;129(18):2519-2525. doi: 10.1182/blood-2017-01-761726. Epub 2017 Feb 24. Blood. 2017. PMID: 28235842 Free PMC article. Clinical Trial.
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. Chen JG, et al. Among authors: tsakmaklis n. Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1. Blood. 2018. PMID: 29496671 Free article.
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Treon SP, et al. Among authors: tsakmaklis n. J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25. J Clin Oncol. 2018. PMID: 30044692 Clinical Trial.
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. Gustine JN, et al. Among authors: tsakmaklis n. Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635. Blood Adv. 2019. PMID: 31570491 Free PMC article.
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklavenitis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, Roccaro A, Branagan AR, Yang G, Ghobrial IM, Castillo JJ. Treon SP, et al. Among authors: tsakmaklis n. J Clin Oncol. 2020 Apr 10;38(11):1198-1208. doi: 10.1200/JCO.19.02314. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083995 Free PMC article. Review.
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials.
Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: tsakmaklis n. Hemasphere. 2020 May 21;4(3):e363. doi: 10.1097/HS9.0000000000000363. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647793 Free PMC article.
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Yang G, Hunter Z, Treon SP. Castillo JJ, et al. Among authors: tsakmaklis n. Blood Adv. 2020 Aug 25;4(16):3952-3959. doi: 10.1182/bloodadvances.2020001963. Blood Adv. 2020. PMID: 32822482 Free PMC article. Clinical Trial.
41 results